Subscribe to RSS
DOI: 10.1055/s-0044-1786854
A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease
Uma agulha no palheiro? Impacto de um painel genético de epilepsia direcionado para a identificação de uma epilepsia metabólica tratável, mas de progressão rápida: CLN2 Support The authors declare that the present study was sponsored by BioMarin Pharmacetical Inc. (Novato, CA, United States).
Abstract
Background Neuronal ceroid lipofuscinoses (NCL) are a group of autosomal recessive, inherited, lysosomal, and neurodegenerative diseases that causes progressive dementia, seizures, movement disorders, language delay/regression, progressive visual failure, and early death. Neuronal ceroid lipofuscinosis type 2 (CLN2), caused by biallelic pathogenic variants of the TPP1 gene, is the only NCL with an approved targeted therapy. The laboratory diagnosis of CLN2 is established through highly specific tests, leading to diagnostic delays and eventually hampering the provision of specific treatment for patients with CLN2. Epilepsy is a common and clinically-identifiable feature among NCLs, and seizure onset is the main driver for families to seek medical care.
Objective To evaluate the results of the Latin America Epilepsy and Genetics Program, an epilepsy gene panel, as a comprehensive tool for the investigation of CLN2 among other genetic causes of epilepsy.
Methods A total of 1,284 patients with epilepsy without a specific cause who had at least 1 symptom associated with CLN2 were screened for variants in 160 genes associated with epilepsy or metabolic disorders presenting with epilepsy through an epilepsy gene panel.
Results Variants of the TPP1 gene were identified in 25 individuals (1.9%), 21 of them with 2 variants. The 2 most frequently reported variants were p.Arg208* and p.Asp276Val, and 2 novel variants were detected in the present study: p.Leu308Pro and c.89 + 3G > C Intron 2.
Conclusion The results suggest that these genetic panels can be very useful tools to confirm or exclude CLN2 diagnosis and, if confirmed, provide disease-specific treatment for the patients.
Resumo
Antecedentes As lipofuscinoses ceroides neuronais (neuronal ceroid lipofuscinoses, NCLs, em inglês) são um grupo de doenças autossômicas recessivas, hereditárias, lisossomais e neurodegenerativas que causam demência progressiva, crises epiléticas, distúrbios de movimento, atraso/regressão da linguagem, deficiência visual progressiva e morte precoce. A lipofuscinose ceroide neuronal tipo 2 (neuronal ceroid lipofuscinosis type 2, CLN2, em inglês), causada por variantes patogênicas bialélicas do gene TPP1, é a única com terapia-alvo aprovada. O diagnóstico laboratorial é realizado por testes específicos, o que leva a atrasos diagnósticos e, consequentemente, prejudica a disponibilização de tratamento. A epilepsia é uma característica comum e clinicamente identificável entre as NCLs, e o início das convulsões é o principal motivo para as famílias buscarem atendimento médico.
Objetivo Avaliar os resultados do Programa de Epilepsia e Genética da América Latina, um painel genético, como uma ferramenta abrangente para a investigação de CLN2 entre outras causas genéticas de epilepsia.
Métodos Um total de 1.284 pacientes com epilepsia sem uma causa específica e que tinham pelo menos 1 sintoma associado à CLN2 foram rastreados em busca de variantes em 160 genes associados à epilepsia ou a distúrbios metabólicos que apresentam epilepsia, por meio de um painel genético.
Resultados Variantes do gene TPP1 foram identificadas em 25 indivíduos (1,9%), sendo que ; 21 apresentavam duas variantes. As duas variantes mais frequentes foram p.Arg208* e p.Asp276Val, e duas variantes novas foram detectadas neste: p.Leu308Pro e c.89 + 3G > C Intron 2.
Conclusão Os resultados sugerem que os painéis genéticos de epilepsia podem ser uma ferramenta útil para confirmar ou excluir o diagnóstico de CLN2 e, se confirmado, fornecer tratamento específico para os pacientes.
Palavras-chave
Lipofuscinoses Ceroides Neuronais - Doenças Neurodegenerativas - Epilepsia - DiagnósticoEditor-in-Chief
Hélio A. G. Teive.
Associate Editor
Lécio Figueira Pinto.
Authors' Contributions
All authors equally contributed through online discussions and by reviewing all draft versions of the texts and tables. All authors approved the submitted version of the manuscript. DRFV provided scientific inputs to the manuscript under no influence of the commercial strategy of BioMarin Brasil Farmacêutica LTDA.
Publication History
Received: 30 January 2024
Accepted: 30 March 2024
Article published online:
19 May 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Charles Marques Lourenço, Juliana Maria Ferraz Sallum, Alessandra Marques Pereira, Paula Natale Girotto, Fernando Kok, Daniel Reda Fenga Vilela, Erika Barron, André Pessoa, Bibiana Mello de Oliveira. A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease. Arq Neuropsiquiatr 2024; 82: s00441786854.
DOI: 10.1055/s-0044-1786854
-
References
- 1 Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 2003; 62 (01) 1-13 DOI: 10.1093/JNEN/62.1.1.
- 2 Guelbert G, Venier AC, Cismondi IA. et al. Neuronal ceroid lipofuscinosis in the South American-Caribbean region: An epidemiological overview. Front Neurol 2022; 13: 920421 DOI: 10.3389/FNEUR.2022.920421/BIBTEX.
- 3 Specchio N, Pietrafusa N, Trivisano M. Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy. Ther Clin Risk Manag 2020; 16: 213-222 DOI: 10.2147/TCRM.S241048.
- 4 Kohlschütter A, Schulz A. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis). Pediatr Endocrinol Rev 2016; 13 (Suppl. 01) 682-688 DOI: Not available
- 5 Lourenço CM, Pessoa A, Mendes CC. et al. Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. J Paediatr Child Health 2021; 57 (04) 519-525 DOI: 10.1111/JPC.15250.
- 6 Kwon CS, Wagner RG, Carpio A, Jetté N, Newton CR, Thurman DJ. The worldwide epilepsy treatment gap: A systematic review and recommendations for revised definitions - A report from the ILAE Epidemiology Commission. Epilepsia 2022; 63 (03) 551-564 DOI: 10.1111/EPI.17112.
- 7 Fisher RS, Acevedo C, Arzimanoglou A. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55 (04) 475-482 DOI: 10.1111/EPI.12550.
- 8 Nevado J, Mergener R, Palomares-Bralo M. et al. New microdeletion and microduplication syndromes: A comprehensive review. Genet Mol Biol 2014; 37 (1, Suppl) 210-219 DOI: 10.1590/S1415-47572014000200007.
- 9 Tumienė B, Peterlin B, Maver A, Utkus A. Contemporary scope of inborn errors of metabolism involving epilepsy or seizures. Metab Brain Dis 2018; 33 (06) 1781-1786 DOI: 10.1007/S11011-018-0288-1.
- 10 Sorge G, Sorge A. Epilepsy and chromosomal abnormalities. Ital J Pediatr 2010; 36: 36 DOI: 10.1186/1824-7288-36-36.
- 11 Zhang D, Liu X, Deng X. Genetic basis of pediatric epilepsy syndromes. Exp Ther Med 2017; 13 (05) 2129-2133 DOI: 10.3892/ETM.2017.4267.
- 12 Wang J, Lin ZJ, Liu L. et al. Epilepsy-associated genes. Seizure 2017; 44: 11-20 DOI: 10.1016/J.SEIZURE.2016.11.030.
- 13 Mazurkiewicz-Bełdzińska M, Del Toro M, Haliloğlu G. et al. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Expert Rev Neurother 2021; 21 (11) 1275-1282 DOI: 10.1080/14737175.2021.1885374.
- 14 Mole SE, Schulz A, Badoe E. et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis 2021; 16 (01) 185 DOI: 10.1186/S13023-021-01813-5.
- 15 Fietz M, AlSayed M, Burke D. et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab 2016; 119 (1-2): 160-167 DOI: 10.1016/J.YMGME.2016.07.011.
- 16 Sampaio LPB, Manreza MLG, Pessoa A. et al. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group. Arq Neuropsiquiatr 2023; 81 (03) 284-295 DOI: 10.1055/S-0043-1761434.
- 17 Leal-Pardinas F, Truty R, McKnight DA. et al. Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease. Epilepsia 2022; 63 (07) e68-e73 DOI: 10.1111/EPI.17269.
- 18 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424 DOI: 10.1038/GIM.2015.30.
- 19 Castillo-Fernandez JE, Spector TD, Bell JT. Epigenetics of discordant monozygotic twins: implications for disease. Genome Med 2014; 6 (07) 60 DOI: 10.1186/S13073-014-0060-Z.
- 20 Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat 2019; 40 (11) 1924-1938 DOI: 10.1002/HUMU.23860.
- 21 Gall K, Izzo E, Seppälä EH. et al. Next-generation sequencing in childhood-onset epilepsies: Diagnostic yield and impact on neuronal ceroid lipofuscinosis type 2 (CLN2) disease diagnosis. PLoS One 2021; 16 (09) e0255933 DOI: 10.1371/JOURNAL.PONE.0255933.
- 22 Lindy AS, Stosser MB, Butler E. et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia 2018; 59 (05) 1062-1071 DOI: 10.1111/EPI.14074.
- 23 Amadori E, Scala M, Cereda GS. et al. Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project. Ital J Pediatr 2020; 46 (01) 92 DOI: 10.1186/S13052-020-00860-1/FIGURES/2.